Chromocell Therapeutics Corporation reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 0.966561 million compared to USD 0.31045 million a year ago. Basic loss per share from continuing operations was USD 0.9.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | -12.94% | -1.13% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 11.81M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- CHRO Stock
- News Chromocell Therapeutics Corporation
- Chromocell Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023